Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw unusually large options trading on Wednesday. Stock investors bought 6,543 put options on the stock. This is an increase of approximately 1,214% compared to the typical volume of 498 put options.

Several equities analysts recently weighed in on the company. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Wednesday, September 27th. Deutsche Bank lifted their target price on Halozyme Therapeutics to $20.00 and gave the company a “buy” rating in a research report on Friday, September 15th. BidaskClub upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, December 12th. Canaccord Genuity lifted their target price on Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Finally, Barclays downgraded Halozyme Therapeutics from an “overweight” rating to a “hold” rating and lifted their target price for the company from $16.00 to $19.00 in a research report on Wednesday, November 22nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. Halozyme Therapeutics presently has a consensus rating of “Hold” and an average price target of $19.14.

Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its position in shares of Halozyme Therapeutics by 6.6% in the third quarter. Rhumbline Advisers now owns 143,342 shares of the biopharmaceutical company’s stock valued at $2,490,000 after acquiring an additional 8,903 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Halozyme Therapeutics by 9.5% in the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock valued at $123,010,000 after acquiring an additional 831,654 shares in the last quarter. Alps Advisors Inc. lifted its position in shares of Halozyme Therapeutics by 10.7% in the third quarter. Alps Advisors Inc. now owns 139,764 shares of the biopharmaceutical company’s stock valued at $2,428,000 after acquiring an additional 13,556 shares in the last quarter. Granite Investment Partners LLC lifted its position in shares of Halozyme Therapeutics by 44.7% in the third quarter. Granite Investment Partners LLC now owns 818,505 shares of the biopharmaceutical company’s stock valued at $14,217,000 after acquiring an additional 252,998 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Halozyme Therapeutics by 7.2% in the third quarter. JPMorgan Chase & Co. now owns 2,868,670 shares of the biopharmaceutical company’s stock valued at $49,915,000 after acquiring an additional 191,476 shares in the last quarter. Institutional investors and hedge funds own 84.45% of the company’s stock.

Halozyme Therapeutics (NASDAQ:HALO) opened at $20.36 on Friday. The firm has a market capitalization of $2,890.00, a price-to-earnings ratio of -29.94 and a beta of 2.09. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01. Halozyme Therapeutics has a 52-week low of $10.74 and a 52-week high of $21.13.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by ($0.04). The company had revenue of $63.73 million for the quarter, compared to analysts’ expectations of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. Halozyme Therapeutics’s revenue for the quarter was up 100.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.23) earnings per share. equities analysts anticipate that Halozyme Therapeutics will post 0.2 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/13/halozyme-therapeutics-target-of-unusually-large-options-trading-halo.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.